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Abstract
Background: Achieving health equity has been identified as a major challenge, both internationally and within
Australia. Inequalities in cancer outcomes are well documented, and must be quantified before they can be
addressed. One method of portraying geographical variation in data uses maps. Recently we have produced
thematic maps showing the geographical variation in cancer incidence and survival across Queensland, Australia.
This article documents the decisions and rationale used in producing these maps, with the aim to assist others in
producing chronic disease atlases.
Methods: Bayesian hierarchical models were used to produce the estimates. Justification for the cancers chosen,
geographical areas used, modelling method, outcome measures mapped, production of the adjacency matrix,
assessment of convergence, sensitivity analyses performed and determination of significant geographical variation
is provided.
Conclusions: Although careful consideration of many issues is required, chronic disease atlases are a useful tool for
assessing and quantifying geographical inequalities. In addition they help focus research efforts to investigate why
the observed inequalities exist, which in turn inform advocacy, policy, support and education programs designed
to reduce these inequalities.
Background
Since the 1978 declaration of Alma-Ata which high-
lighted the need to address inequalities in health status
[1], there have been important advancements for cancer
outcomes. Many developed nations have seen improve-
ments in cancer survival, notably for colorectal cancer,
breast cancer, prostate cancer, non-Hodgkin lymphoma
and leukaemia [2,3]. Also, incidence and mortality rates
for some cancers have declined [4]. However, notable
inequalities in these outcomes persist, with numerous
international studies reporting disparities in cancer out-
comes across socioeconomic status or urban/rural cate-
gories [5-7].
Within Australia, one of the greatest recognised health
challenges is achieving health equity for all [8]. Cancer
patients living in rural and disadvantaged areas are gen-
erally more likely to be diagnosed with advanced cancer
and have poorer survival outcomes [9,10]. Often these
areas have a higher prevalence of risk factors such as
smoking, obesity and lower levels of physical activity
[11,12]. Distance is also important, with cancer patients
in rural areas having reduced access to cancer care ser-
vices [13-15].
Inequalities need to be quantified before they can be
addressed. Maps have been used to portray geographical
data for a range of diseases since the mid-1800s, includ-
ing cancer [16]. By providing a visual representation of
cancer outcomes, geographic patterns of disease are able
to be identified and effectively addressed [17]. For exam-
ple, cancer mortality maps showed high mortality from
oral cancer in south-eastern United States of America
which led to the identification of snuff dipping as a risk
factor [18]. Similarly, mammography screening efforts
were intensified after finding low in-situ breast cancer
incidence rates from mapped data in north-eastern Con-
necticut [19].
We recently developed thematic maps showing the
geographical variation in cancer incidence and survival
across Queensland, Australia [20]. With a population of
4.2 million [21] and covering an area of 1.9 million
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decentralized population [22] and the highest incidence
of cancer [23]. As there is increasing interest in produ-
cing disease maps [24-30], it is hoped that by document-
ing the processes and rationale behind the many
decisions made during the development of this Cancer
Atlas, it may assist others seeking to produce similar
types of chronic disease atlases.
Methods
Ethical approval to conduct this study was obtained
from the Queensland Health - Central Office Commit-
tee Human Research Ethics Committee (HREC/09/
QHC/25). Approval to extract the data was obtained
from the Chief Executive Officer - Centre for Health
Care Improvement, Queensland Health, under delega-
tion by the Director-General, Queensland Health.
Data sources
The Queensland Cancer Registry (QCR) supplied de-
identified data on all primary invasive cancers diagnosed
among Queensland residents during 1996 to 2007. The
QCR is a population-based cancer registry that main-
tains a record of all cases of cancer diagnosed in
Queensland since 1982, with data currently available to
the end of 2007 [31]. Survival status of all cancer
patients is obtained through routine linkage with the
(Australian) National Death Index, enabling deaths of
cancer patients who die interstate to be identified.
Across all cancers, 91% of cancers registered by the
Queensland Cancer Registry in 2007 were histologically
verified and 1.9% were registered based on death certifi-
cate only (DCO) [31]. Cases with unknown age group
(0.001% of all cancers) were excluded from the analyses.
Estimated resident population data grouped by age
group (0-4, 5-9..., 80-84, 85+), sex, year and statistical
local area (SLA) were obtained from the Australian
Bureau of Statistics. To calculate the expected popula-
tion mortality estimates, de-identified unit record mor-
tality data for all causes of death for Queensland
residents were also obtained from the Australian Bureau
of Statistics (ABS) [32].
Choice of cancers
The Cancer Atlas described spatial variation in the lead-
ing cancers diagnosed in Queensland during the study
period (Table 1). These included the (Australian)
National Health Priority Area cancers of colorectal can-
cer, lung cancer, breast cancer, cervical cancer, prostate
cancer and non-Hodgkin’s lymphoma. Although a prior-
ity cancer, variation in non-melanocytic skin cancer was
not assessed, since it is not routinely reported by popu-
lation-based cancer registries in Australia. When a can-
cer was not gender specific, results were calculated for
each gender. The only exception to this was breast can-
cer which was reported for females only due to the very
small number of breast cancers diagnosed among males.
Geographical areas
SLAs were used to define the geographical areas. These
are part of the Australian Standard Geographic Classifi-
cation (ASGC) used by the ABS [33] and are often
Table 1 Cancers examined for geographic variation, Queensland, 1998-2007
Type of cancer ICD-O3 code Total number males diagnosed Total number females diagnosed
All invasive cancers C00-C80 (excluding C44 (M805 to 811)) 105,053 82,470
Bladder cancer C67 5,034 1,571
Brain cancer C70, C71, C72 1,504 1,067
Breast cancer C50 Not included 22,420
Cervical cancer C53 Not applicable 1,639
Colorectal cancer C18-C20 and C218 13,405 10,871
Kidney cancer C64-C66 and C68 3,117 1,883
Leukaemia M980-M994 3,084 2,094
Lung cancer C33-C34 11,152 5,683
Melanoma C44 and M872-M879 13,793 10,110
Myeloma M973 1,192 913
Non-Hodgkin lymphoma M959, M967-M971 3,547 2,889
Oesophageal cancer C15 1,464 639
Ovarian cancer C56 Not applicable 2,120
Pancreatic cancer C25 1,940 1,706
Prostate cancer C61 25,222 Not applicable
Stomach cancer C16 2,193 1,070
Thyroid cancer C73 765 2,221
Uterine cancer C54 Not applicable 3,112
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who are responsible for service provision and infrastruc-
ture at the local and regional level.
The ABS adjusts the geographical boundaries of SLAs
according to changes in the population composition
over time. To ensure statistical analyses referred to the
same geographical area for the entire study period, all
SLAs were mapped to the boundaries used for the 2006
ASGC. The mapping process was conducted within the
Queensland Cancer Registry, and matched the suburb
and postcode at diagnosis to the 2006 National Local-
ities Index [34]. There were 478 SLAs in Queensland in
2006 [33].
Estimates of incidence and survival were also exam-
ined by area-level socioeconomic status and rurality.
Socioeconomic status was defined using the Socioeco-
nomic Indexes for Areas (SEIFA) Index of Relative
Socioeconomic Advantage and Disadvantage (IRSAD)
compiled by the ABS [35]. Queensland SLAs were
ranked from the most disadvantaged to the most advan-
taged and then divided into quintiles, based on a variety
of data items such as the percentages of: people with
high income, people unemployed, households paying
cheap rental, households with no car and households
with broadband internet connection. Rurality was
defined using the ARIA+ (Accessibility/Remoteness
Index for Australia plus) classification [36], which
defines remoteness on the basis of five categories: major
city, inner regional, outer regional, remote and very
remote. ‘Remote’ and ‘very remote’ categories were com-
bined together. The level of remoteness is determined
by road-based distance to services.
Methods to generate estimates
T op r o d u c eau s e f u lm a po nas m a l l - a r e as c a l ei ti s
important to have estimates that are robust, or relatively
insensitive to outliers, across small areas. If estimates
are not robust, these outliers from areas which are often
based on very small populations, are more likely to be
disproportionately influential, and thus compromise the
overall interpretation of the map.
Modelling or smoothing methods are commonly used to
generate robust estimates for small geographical areas. As
traditional regression models are unable to incorporate
spatial correlation, approaches which enable hierarchical
structure to be incorporated such as generalised linear
mixed models may be used. These may be calculated
using either Bayesian, multi-level, or likelihood-based
models, however, Bayesian methods do not require the
restrictive distributional assumptions in the other models
(such as, for example, Gaussian random effects) [37].
Smoothing methods require no distributional assumptions
and include interpolation methods, or non-parametric
such as kernel regression, kriging and partition methods
[38,39]. They are generally easier and faster to perform
than modelling, but a comparison of various modelling
and smoothing methods suggested Bayesian models per-
formed better than the smoothing methods [40].
Bayesian models incorporate empirical Bayes and fully
Bayes methods. In both types of Bayesian models, para-
meters are assigned probability distributions, usually
based on plausible or expected values, and termed
‘priors’. Fully Bayesian methods assign second stage
priors to the variance controlling this distribution
(’hyperparameters’). In contrast, empirical Bayes methods
estimate the hyperparameter from the distribution of the
data [41]. Therefore, empirical Bayes methods give satis-
factory point estimates, but are unlikely to provide accu-
rate estimates of the associated uncertainty [42].
Fully Bayesian models are becoming increasingly com-
mon in disease mapping [43]. Advantages of Bayesian
models in comparison to other methods include the
ease of drawing strength from neighbouring regions so
estimates are more reliable and robust, as well as pro-
viding better quantification of the uncertainty surround-
ing the calculated estimates [41,44]. Also, Bayesian
methods enable structuring of more complicated mod-
els, inferences and analyses [45]. Other cancer atlases
which have used fully Bayesian methods include NSW
(Australia) [46] and Limburg (Belgium) [47] (Table 2).
Outcome measures - what to map?
Incidence estimates
Incidence is defined as the number of new invasive can-
cer cases diagnosed within a given time period. When
examining incidence in small areas, the traditionally
used estimate is the SIR (indirectly Standardised Inci-
dence Ratio). The SIR is an estimate of relative risk
within each area which compares the observed counts
against an expected number of counts, based on the
population size.
However, limitations associated with the SIR estimates
have been previously noted [38]. For example, large dif-
ferences can be observed in the SIR estimates even with
relatively small changes in incidence counts, and areas
with no cases automatically receive an SIR of zero,
regardless of the expected counts [40].
Modelling the SIR via spatial or Bayesian methods
overcomes many of these problems by producing more
reliable and robust estimates. Although there are many
advantages to using a modelled SIR, they reflect the
comparison of SLA-specific estimates against the
Queensland average and not comparisons between SLA-
specific estimates themselves. The latter interpretation
may be biased if the SLAs have different population age
structures and the outcome measure varies by age. For
this reason the maps must be interpreted in terms of
which areas are higher or lower than the Queensland
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parative Incidence Figure (CIF, which is the ratio of the
local to national (or whole region) directly standardized
rates, i.e. rates weighted by age groups using an external
population), have been proposed to overcome this issue,
but these have their own disadvantages, including larger
standard errors [49]. In light of these evaluations, the
modelled SIR was adopted.
Survival estimates
Typically, cancer atlases have tended to report variations
in cancer mortality, rather than cancer survival (Table 2).
However spatial variations in cancer mortality reflect dif-
ferences according to where people die, which may not
be where they resided when diagnosed or treated. Mor-
tality data are also prone to bias from death certificate
inaccuracies in cause of death classification [50]. In con-
trast, mapping cancer survival, which is the percentage of
patients who survive for a given time after diagnosis, esti-
mates the variation in outcomes based on where people
lived when diagnosed. Since treatment generally occurs
shortly following diagnosis, this better reflects the poten-
tial impact of barriers to treatment and support services.
Survival after the diagnosis of cancer is the most
important single measure for monitoring and evaluating
the early diagnosis and treatment components of cancer
control [51]. When examining cancer survival using
population-based data, relative survival is often the pre-
ferred method as it provides an estimate of the net can-
cer survival without errors from cause of death
misclassification, including difficulties in assigning cause
of death when cancer was a contributing cause, but may
not be completely responsible for the death [52,53].
Relative survival aims to measure deaths in excess of
what would be expected, that is, the proportion of
Table 2 Selected Cancer Atlases published from 1995 onwards
Region Time
period
Outcome Statistic
mapped
Smoothing method N
regions
a
N cancers
mapped
b
Presentation
method
c
Canada [63] 1986-1990 Incidence CIF None 290 17 (M, F or P) Ecumene
Europe [64] ~1981-1990 Incidence
Mortality
DSR Floating average of neighbouring
rates for non-cities
Not
stated
31 (M, F) Isopleth
India [65] 2001-2002 Incidence DSR None 593 1 (M, F) Areal
Limburg [66]
(Belgium)
1996-1998 Incidence SIR Poisson-Gamma and CAR Bayesian
models
44 5 (M, F) Areal
Netherlands [67] 1989-2003 Incidence DSR Floating average of neighbouring
rates for non-cities
458 11 (M, F) Isopleth
New York [68] (USA) Not stated Incidence DSR None 62 12 (M, F) Areal
New South Wales
[46] (Australia)
1998-2002 Incidence
Mortality
SIR, SMR CAR Bayesian model 192 22 - inc (M, F)
12-mort (M, F)
Areal
Pennsylvania [69]
(USA)
1994-2002 Incidence DSR None 67 2 (M, F, P) Areal
Queensland [20]
(Australia)
1998-2007 Incidence
Survival
SIR, RER Bayesian hierarchical models: BYM
and relative survival
478 19 (M, F) Areal
South Australia [70]
(Australia)
1991-2000 Incidence
Mortality
DSR None 117 11 (P) Ecumene
Spain [71] 1987-1995 Mortality SIR Non-parametric empirical Bayes
estimation method
2218 4 (M, F) out of
14 maps
Areal
Sweden [72] 1971-1989 Incidence DSR, CIF None 286 37 (M, F) Areal
UK [73] 2003-2005 Incidence
Survival Mortality
DSR, RS None 350 17 (M, F, P) Areal
UK/Ireland [74] 1991-2000 Incidence
Mortality
CIF or CMF None 127 21 (M, F) Areal
USA [75] 1950-1994 Mortality DSR, CIF None 3055 41 (M, F) Areal
a. When multiple areas are available, as for some of the online Atlases, the number of regions is the number at the most detailed level.
b. M = males, F = females and P = persons.
c. Ecumene means only populated areas were coloured, Areal indicates that each individual region was coloured, and Isopleth means a continuous gradient was
used.
BYM = Besag, York and Mollié
CAR = Conditional AutoRegressive.
CIF/CMF = Comparative Incidence/Mortality Figure, and is the ratio of the DSR of the area to the DSR of the entire region or country.
DSR = Directly age Standardised Rates.
RER = Relative Excess Risk of death.
RS = Relative Survival.
SIR/SMR = indirectly Standardised Incidence/Mortality Ratio.
Cramb et al. International Journal of Health Geographics 2011, 10:9
http://www.ij-healthgeographics.com/content/10/1/9
Page 4 of 11cancer patients alive x years after diagnosis in the
hypothetical situation where the cancer in question is
the only possible cause of death. Relative survival is
modelled via an excess mortality model, which contrasts
the mortality in the general population with the mortal-
i t yo fc a n c e rp a t i e n t s .T h ed i f f e r e n c ei sa s s u m e dt ob e
due to cancer-related deaths (’excess mortality’). This
model generates the excess hazard, also called relative
excess risk (RER).
The median smoothed RER (i.e. exponential of the
sum of the spatial and random heterogeneity compo-
nents) was mapped. Similar to the interpretation of the
SIR, the RER is a comparison against the State average,
and comparison between areas is not recommended.
Bayesian hierarchical models
Incidence
For incidence models the Besag, York and Mollié (BYM)
model was used, as it has been shown to have desirable
properties for disease mapping [43]. This model is speci-
fied as:
ye
uv
ii i
ii i
∼ Poisson( )
log( )

 =++
where ei is the expected number of cases for the ith
SLA, θi is the standardised incidence ratio, a is the over-
all level of relative risk, ui is the spatial component
modelled with the conditional autoregressive (CAR)
prior, and vi is the unstructured random effects (which
has a normal distribution centered around zero). Input
data were aggregated over 1998 to 2007. Since incidence
is likely to differ by gender, estimates for males and
females were generated separately.
Since this is a fully Bayesian model, priors were speci-
fied for a, ui and vi.T h ep r i o rf o ra was given a vague
normal distribution with mean 0 and variance of 1.0 ×
10
10. The prior distributions for ui and vi required sensi-
tivity analyses, and are discussed below.
Relative survival
For relative survival, a recommended approach is to
model excess mortality under a generalized linear model
based on collapsed data using exact survival times and a
Poisson assumption [52]. The basic version of this
model was extended to include spatial and random
effects, similar to Fairley et al [54].
d
dy u v
kji kji
kji kji kji j k i i
~( )
log( ) log( )
*
Poisson
x

  −= + ++ +
Where ykji is person-time at risk in the kth age group,
the jth follow up interval and the ith SLA, dkji
* is the
expected number of deaths due to causes other than the
cancer of interest, aj is the intercept (which varied by
follow-up year), bk is the coefficient of the predictor
variable vector × (representing the broad age groups), vi
is the unstructured random effects (which has a normal
distribution) and ui is the spatial component modelled
with the CAR prior. Both a and b were given priors
with normal distributions having mean 0 and variance
1.0 × 10
6. The model was run separately for males and
females. Broad age groups were included in the model
to prevent bias due to differing age structures between
SLAs.
All cases considered ‘at risk’ during 1998 to 2007 were
included. Since the earliest year of data was 1996, this
meant that any cases diagnosed from 1996 onwards
which were alive with up to 5 years follow-up at some
stage during 1998-2007 were included. Cases alive on
the 31
st December 2007 were considered censored.
This model excluded persons aged 90 years or older at
time of diagnosis, those whose diagnosis was based on
death certificate or autopsy only, or those with a survival
time of zero days or less. In total, this was 3.3% of the
records from 1996-2007.
Adjacency matrix
Since the Bayesian models incorporate information from
neighbouring regions, it is necessary to specify the defi-
nition of which SLAs are considered neighbours. An
adjacency matrix is generated to apply these definitions
in the Bayesian model. Using the standard terminology
for adjacency options, which follow the possible moves
of chess pieces, we used the “Queen” definition, so that
SLAs were considered to be neighbours if they shared a
common border [55]. The adjacency matrix was calcu-
lated using the program GeoDa [56] using 1
st order
queen adjacencies. Although it is possible to use higher-
order weights than first-order (e.g. second-order weights
will include neighbours of neighbours), this was not
considered useful for this analysis due to the much den-
ser neighbourhood matrix and, particularly in rural
areas of the state, the very large distances between sec-
ond-order neighbouring SLAs.
Due to the large number of island SLAs in Queensland,
18 regions originally had no neighbours. Since estimates
will not be smoothed unless a region has neighbours the
default neighbourhood matrix was adjusted to ensure all
regions had at least one neighbour. Additional neigh-
bours were incorporated by considering they could share
a border even if separated by a river, or a sea. In particu-
lar, most of the Far North islands were grouped together,
with some mainland areas also included to ensure
enough strength was provided to generate meaningful
estimates that were able to converge.
Computation
Models were run using WinBUGS [57] interfaced with
Stata [58] (using the wb commands written by John
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period of 100,000 iterations (incidence models) and
250,000 iterations (survival models) followed by 100,000
iterations. To decrease the correlation between iterations
a subsample of every tenth iteration was kept. Only one
chain was run for each estimate.
Assessing convergence
Convergence was assessed using visual examination of
trace, density and autocorrelation plots, as well as the
Geweke diagnostic [60]. Geweke diagnostics were calcu-
lated as the difference between the means for the first 1000
iterations (10%) that were kept and the final 5000 iterations
(50%), divided by the asymptotic standard error of the dif-
ference. These were generated for the SIR or RER estimates
for all 478 SLAs, and any estimate that had a Geweke esti-
mate with a p-value of less than 0.01 was considered unli-
kely to have converged. To save disk space and processing
time, trace and density plots were only generated for 5% (n
= 24) of the SLAs, composed of SLAs of concern due to
small numbers as well as a random selection.
Sensitivity analyses
For these types of models, and particularly when data
are sparse, it is vital to carefully consider the choice of
prior and compare the effects of alternate priors. The
priors used on the distribution for the variance of the
spatial and random effects components may particularly
influence the results.
There were three stages to conducting the sensitivity
analyses. First, the literature was searched to determine
what priors were being used in similar models. Many
BYM models were found, however, there were few
examples of Bayesian relative survival models containing
spatial components. As there was no other source of
information relevant to the study at hand on which to
base informative priors, a range of non-informative
priors were used for the relative survival models. Sec-
ond, the performance of each prior was evaluated. Since
the potential influence of the prior will be more pro-
nounced for scarce data, Tables 3 and 4 show some of
the comparative numbers for a less common cancer -
oesophageal cancer in males. In addition to these,
observed values were plotted against those predicted by
the model and quantile-quantile plots were examined.
Third, convergence was examined, as outlined earlier.
Lack of convergence could indicate a poor model, or it
may simply indicate a longer burn-in period is required.
Monitoring the estimate over the entire number of
iterations (including burn-in) would show whether it is
likely convergence will eventually be reached. In tables 3
and 4 the proportion of SLAs for which the SIR or RER
estimate did not converge after discarding 50,000 itera-
tions is shown.
Table 3 Sensitivity analyses for oesophageal cancer incidence among males
Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6
Distribution of SIR
Mean 100.8 99.4 101.5 100.7 100.6 103.6
Standard deviation 10.2 30.8 16.3 14.5 13.5 23.2
Maximum 140.6 455.1 181.2 169.5 166.4 201.8
75% Quartile 107.2 113.1 111.7 110.2 109.4 109.8
Median 96.5 93.5 95.1 95.6 95.9 95.7
25% Quartile 93.3 78.7 89.4 89.9 90.7 90.2
Minimum 87.4 55.9 79.6 79.3 80.0 79.8
90% ratio
1 1.3 2.3 1.6 1.5 1.5 1.6
pD
2 34.112 138.047 51.305 53.828 53.709 54.098
DIC
3 1652.57 1660.32 1650.62 1648.51 1651.02 1650.71
Spatial fraction
4 0.56 0.44 0.63 0.48 0.52 0.57
Percent SLAs with Geweke <0.01 for SIR 41.0% 1.9% 3.3% 9.4% 10.3% 10.5%
Notes:
1. The 90% ratio is calculated as the 95
th percentile divided by the 5
th percentile of the smoothed SIR estimates.
2. pD represents the effective number of parameters in the model. Larger values indicate less smoothing of estimates.
3. DIC = Deviance Information Criterion. Smaller values (of at least 5 below) indicate a better model fit.
4. The spatial fraction estimates the relative contribution of spatial and unstructured heterogeneity, and is calculated as:
Spatialfraction =
+


marginal
marginal
2
22
where marginal
2 = marginal spatial variance, s
2= marginal variability of the unstructured random effects between areas. A value close to 1 indicates the
spatial heterogeneity dominates, whereas a value close to 0 indicates the unstructured heterogeneity dominates.
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cers were examined (for incidence: oesophageal, brain,
myeloma; for survival (based on number of deaths):
oesophageal, thyroid), as well as a more common one
(incidence: melanoma; survival: pancreatic).
For both the incidence and survival models, u repre-
sents the spatial component, while v represents the ran-
dom component. These components were each given
hyperprior distributions, as below:

 
 i
ij u i i
N
uu i j N
~( )
[| ] ~( ) ,, ,
0
2
22
,
≠
where 





i
ji j
jji j
i
u
ji j
=
=
1
2
2
Σ
Σ
Σ
ωij = 1 if SLAs i, j are adjacent (or 0 if they are not).
The τ values control the variability of u and v.A ss u c h ,
the distribution can be specified using τ or s,w h i c hi s
the square root of the inverse of τ (variance = s
2).
The following priors were compared for the incidence
model:
1. τu ~ Gamma(0.5, 0.0005), τv ~G a m m a ( 0 . 5 ,
0.0005)
2. τu ~ Gamma(1,1), τv ~ Gamma(7.801, 2.793)
3. τu ~ Gamma(0.1, 0.1), τv ~ Gamma(0.001, 0.001)
4. τu ~ Gamma(0.1, 0.01), τv ~ Gamma(0.1, 0.01)
5. Reparameterised on s: su ~U n i f o r m ( 0 , 1 ) ,sv ~
Uniform (0,1)
6. Reparameterised on s: su ~ Uniform (0,1000), sv
~ Uniform (0,1000)
Prior 1 shrunk the estimates more than any other (the
pD value is lower than the others, and the standard devia-
tion smaller) (Table 3). Prior 2 induced far less shrinkage
than the others (higher pD and standard deviation). Prior
2 also had a larger DIC (greater than 6 above the others),
indicating worse model fit. Priors 3 to 6 gave fairly similar
results, although prior 6 had a larger standard deviation.
I tw a sd e c i d e dt ou s ep r i o r3a si tp r o v i d e dc o n s i s -
tently plausible results and converged well across the
range of cancers examined.
For the survival model, the following non-informative
priors were compared:
1. τu ~ Gamma(0.5, 0.001), τv ~ Gamma(0.5, 0.001)
2. τu ~ Gamma (0.1, 0.1), τv ~ Gamma(0.001, 0.001)
3. τu ~ Gamma(0.1, 0.01), τv ~ Gamma(0.1, 0.01)
4. τu ~ Gamma(0.5, 0.0005), τv ~G a m m a ( 0 . 5 ,
0.0005)
5. Reparameterised on s: su ~U n i f o r m ( 0 , 1 ) ,sv ~
Uniform(0,1)
6. Reparameterised on s: su ~ Uniform(0,1000), sv
~ Uniform(0,1000)
Table 4 Sensitivity analyses for oesophageal cancer survival among males
Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6
Distribution of RER
Mean 100.2 100.7 100.4 100.1 100.4 100.0
Standard deviation 6.5 11.5 8.2 3.8 9.3 0.3
Maximum 119.6 140.7 127.6 111.3 129.5 102.1
75% Quartile 105.3 105.0 105.7 102.6 106.3 100.2
Median 98.0 97.3 97.7 99.2 97.0 100.0
25% Quartile 95.2 92.6 94.7 97.2 93.7 99.8
Minimum 80.9 63.4 75.0 89.4 72.5 98.3
90% ratio
1 1.2 1.4 1.3 1.1 1.3 1.0
pD
2 23.988 36.021 33.105 18.663 30.524 18.218
DIC
3 3690.23 3690.27 3691.24 3691.32 3690.07 3694.96
Spatial fraction
4 0.62 0.87 0.51 0.48 0.80 0.00
Percent SLAs with Geweke <0.01 for RER 89.3% 9.8% 10.5% 19.5% 21.5% 63.0%
Notes:
1. The 90% ratio is calculated as the 95
th percentile divided by the 5
th percentile of the smoothed RER estimates.
2. pD represents the effective number of parameters in the model. Larger values indicate less smoothing of estimates.
3. DIC = Deviance Information Criterion. Smaller values (of at least 5 below) indicate a better model fit.
4. The spatial fraction estimates the relative contribution of spatial and unstructured heterogeneity, and is calculated as:
Spatialfraction =
+


marginal
marginal
2
22
Where marginal
2 = marginal spatial variance, s
2= marginal variability of the unstructured random effects between areas. A value close to 1 indicates the
spatial heterogeneity dominates, whereas a value close to 0 indicates the unstructured heterogeneity dominates.
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Page 7 of 11Prior 3 was chosen because it demonstrated greater
convergence properties across the range of cancers
examined, while restricting the results to a narrower
range of smoothed estimates than Prior 2 (Table 4).
Production of maps
A thematic scheme was chosen, with colours determined
using color brewer http://colorbrewer2.org under the
specifications of a diverging colour-scheme of 5 cate-
gories which are suitable for print and colour-blind
friendly (Figure 1). The SIRs and RERs were categorised
as 10% above and 30% above the State average, and the
inverse of these for the lower cut-offs. There is great
variability in the categories used in other atlases, but
these fairly broad categories were used to reduce the
probability of reporting spuriously significant differences.
Mapping alternative measures, such as the posterior
probability of exceeding a certain value, were consid-
ered, but were deemed unsatisfactory due to difficulties
in interpretation and the lack of information provided in
regards to the size of the risk [27,44]. Therefore we used
graphs to show the precision of the mapped estimates.
Graphs
To supplement the information provided in the maps,
a graph showing the ranked SIR or RER with the asso-
ciated 95% credible interval for each SLA was pro-
vided (Figure 2). Horizontal box plots of the SIR or
RER estimates by socioeconomic status and rurality
were also provided to provide additional information
about where the extent of variability across the state
(Figure 2). Since a primary purpose of the model was
to provide overall estimates of variability across the
State, we did not include these additional variables in
the model.
Additional data included
For each cancer with significant variation, SIR or RER esti-
mates with 95% credible intervals were also provided by
socioeconomic and rurality classifications. To calculate
these, each iteration of the 10,000 iterations had the mod-
elled observed value (incidence) and the adjusted deaths
value (survival) calculated as above. For survival (which
incorporated age group and time period) these were
summed to give 10,000 iterations for each SLA. Each SLA
was then grouped into rurality or socioeconomic status
Figure 1 An example of the incidence (risk of diagnosis) and survival (risk of death within 5 years of diagnosis) maps for all invasive
cancers, males.
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were divided by the original expected values to produce
10,000 SIR or RER estimates by rurality and socioeco-
nomic status categories. The median of these 10,000 was
used as the SIR or RER point estimate, and the 2.5 and
97.5 percentiles used to provide the lower and upper cred-
ible interval estimates, respectively.
Determining whether observed variation is significant
Once the results have been produced and mapped, it is
important to determine whether the apparent variation
reflects true geographic differences. Therefore, a test for
global clustering was conducted. Multiple tests are avail-
able [19], such as Besag-Newell’sR ,M o r a n ’sI ,O d e n ’s
Ipop, but we elected to use Tango’s MEET (Maximised
E x c e s sE v e n t sT e s t )[ 6 1 ]a si th a sb e e ns h o w nt op e r -
form well across a variety of datasets [19].
A small p-value from Tango’s MEET indicates that
estimates differ between regions. As is consistent with
standard statistical analysis [62], adjusted p-values from
the Tango’s MEET statistic below 0.01 were considered
to strongly indicate spatial variation, while values
between 0.05 and 0.01 were moderately indicative of
variation. Values of 0.05 or above were considered to
not be significant, however two categories were defined.
Values between 0.05 and 0.10 were considered to pro-
vide only weak evidence of geographic variation, while
values above 0.10 no evidence of geographical variation.
Since Tango’s MEET is calculated using Monte Carlo
replications, it is expected that there could be slight var-
iations in the results. To increase our confidence that
the final classification of geographic variation was stable,
Tango’s MEET was run an additional 5 times for each
cancer and gender combination. There were only two
cases where the final classification did change for
different replication, and so these cancers were assigned
to the more conservative, less significant category.
Input for Tango’s MEET requires an observed and
expected value. Since the modelled results were of inter-
est, the modelled observed value needed to be calculated.
For the incidence data, the observed value was calculated
by the smoothed SIR median value multiplied by the
expected value to produce a modelled observed value.
For the relative survival model, the adjusted deaths for
each data point were calculated as: (person-time at risk ×
exp
follow-up time ×e x p
age group × RER) + expected number
of deaths due to causes other than the cancer of interest.
i.e. ()
* yd kji
u
kji
j ki i ××× +
+ eee
 
These were then added together for each SLA to pro-
vide the input data for Tango’s MEET.
Conclusions
Chronic disease atlases are a useful tool for assessing
and quantifying geographical inequalities, as well as
assisting to focus research efforts in investigating why
the observed inequalities exist. When developing these
atlases, a myriad of decisions concerning how to model
and present the results need to be made and this paper
presents one decision-making algorithm used to gener-
ate a cancer atlas.
There are several priority areas for future consideration
in disease mapping including communicating spatial
results, particularly finding ways to present the uncer-
tainty surrounding the results; and the development and
use of alternative statistical models such as classification
and regression tree (CART) models. In addition, more
detailed statistical models can be developed to investigate
the impact of rurality, area-level and individual level
socioeconomic status as well as temporal changes.
Figure 2 An example of the incidence graphs for all invasive cancers, males.
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Page 9 of 11As with all chronic disease atlases, it is hoped that the
presented variations in outcomes will stimulate further
research efforts to investigate the reasons underlying the
disparities and inform advocacy, policy, support and
education programs to effectively address these, so that
health equity will become a reality.
The full report is available (from February 2011) at:
http://www.cancerqld.org.au/pdf/cancer_atlas.pdf
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